Global Glucagon Like Peptide-1 (GLP-1) Agonists Market by Manufacturers, Regions, Type and Application, Forecast to 2023
- SKU ID : GIR-GIR1806140188 12469457
- |
- Publishing Date: 05-Jul-2018
- |
- Region: Global
- |
- No. of pages: 130
Glucagon like peptide-1 (GLP-1) agonists is the agonists of the GLP-1 receptor. This class of drugs is used for the treatment of type 2 diabetes. One of their advantages is over older insulin secretagogues, such as sulfonylureas or meglitinides, and they have a lower risk of causing hypoglycemia.
Scope of the Report:
This report focuses on the Glucagon Like Peptide-1 (GLP-1) Agonists in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.
United States is the largest consumer of Glucagon like peptide-1 (GLP-1) agonists with the production market share of 35% and the consumption market share of 44% in 2015.
The second place is Europe, following North America with the production market share of 63% and the consumption market share of 28% in 2015.
Market competition is intense. Novo Nordisk, AstraZeneca, Eli Lilly, GSK, Sanofi are the leader of the industry, and hold the key technologies and patents, with high-end customers. They have formed global market channel of the industry. However, with the future expanding market, there will be more manufacturers in the future.
The worldwide market for Glucagon Like Peptide-1 (GLP-1) Agonists is expected to grow at a CAGR of roughly 14.3% over the next five years, will reach 11700 million US$ in 2023, from 5240 million US$ in 2017, according to a new GIR (Global Info Research) study.
Market Segment by Manufacturers, this report covers
Novo Nordisk
AstraZeneca
Eli Lilly
GSK
Sanofi
Bristol-Myers Squibb
Amylin
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia etc.)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
Exenatied
Liraglutide
Lixisenatide
Albiglutide
Dulaglutide
Market Segment by Applications, can be divided into
Hospital
Pharmacy
Other
There are 15 Chapters to deeply display the global Glucagon Like Peptide-1 (GLP-1) Agonists market.
Chapter 1, to describe Glucagon Like Peptide-1 (GLP-1) Agonists Introduction, product scope, market overview, market opportunities, market risk, market driving force;
Chapter 2, to analyze the top manufacturers of Glucagon Like Peptide-1 (GLP-1) Agonists, with sales, revenue, and price of Glucagon Like Peptide-1 (GLP-1) Agonists, in 2016 and 2017;
Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2016 and 2017;
Chapter 4, to show the global market by regions, with sales, revenue and market share of Glucagon Like Peptide-1 (GLP-1) Agonists, for each region, from 2013 to 2018;
Chapter 5, 6, 7, 8 and 9, to analyze the market by countries, by type, by application and by manufacturers, with sales, revenue and market share by key countries in these regions;
Chapter 10 and 11, to show the market by type and application, with sales market share and growth rate by type, application, from 2013 to 2018;
Chapter 12, Glucagon Like Peptide-1 (GLP-1) Agonists market forecast, by regions, type and application, with sales and revenue, from 2018 to 2023;
Chapter 13, 14 and 15, to describe Glucagon Like Peptide-1 (GLP-1) Agonists sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source
Scope of the Report:
This report focuses on the Glucagon Like Peptide-1 (GLP-1) Agonists in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.
United States is the largest consumer of Glucagon like peptide-1 (GLP-1) agonists with the production market share of 35% and the consumption market share of 44% in 2015.
The second place is Europe, following North America with the production market share of 63% and the consumption market share of 28% in 2015.
Market competition is intense. Novo Nordisk, AstraZeneca, Eli Lilly, GSK, Sanofi are the leader of the industry, and hold the key technologies and patents, with high-end customers. They have formed global market channel of the industry. However, with the future expanding market, there will be more manufacturers in the future.
The worldwide market for Glucagon Like Peptide-1 (GLP-1) Agonists is expected to grow at a CAGR of roughly 14.3% over the next five years, will reach 11700 million US$ in 2023, from 5240 million US$ in 2017, according to a new GIR (Global Info Research) study.
Market Segment by Manufacturers, this report covers
Novo Nordisk
AstraZeneca
Eli Lilly
GSK
Sanofi
Bristol-Myers Squibb
Amylin
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia etc.)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
Exenatied
Liraglutide
Lixisenatide
Albiglutide
Dulaglutide
Market Segment by Applications, can be divided into
Hospital
Pharmacy
Other
There are 15 Chapters to deeply display the global Glucagon Like Peptide-1 (GLP-1) Agonists market.
Chapter 1, to describe Glucagon Like Peptide-1 (GLP-1) Agonists Introduction, product scope, market overview, market opportunities, market risk, market driving force;
Chapter 2, to analyze the top manufacturers of Glucagon Like Peptide-1 (GLP-1) Agonists, with sales, revenue, and price of Glucagon Like Peptide-1 (GLP-1) Agonists, in 2016 and 2017;
Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2016 and 2017;
Chapter 4, to show the global market by regions, with sales, revenue and market share of Glucagon Like Peptide-1 (GLP-1) Agonists, for each region, from 2013 to 2018;
Chapter 5, 6, 7, 8 and 9, to analyze the market by countries, by type, by application and by manufacturers, with sales, revenue and market share by key countries in these regions;
Chapter 10 and 11, to show the market by type and application, with sales market share and growth rate by type, application, from 2013 to 2018;
Chapter 12, Glucagon Like Peptide-1 (GLP-1) Agonists market forecast, by regions, type and application, with sales and revenue, from 2018 to 2023;
Chapter 13, 14 and 15, to describe Glucagon Like Peptide-1 (GLP-1) Agonists sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source
Frequently Asked Questions
This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.
- By product type
- By End User/Applications
- By Technology
- By Region
The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.
Please Select a Format
